The future for regenerative medicine, advanced therapies and stem cell research
17th April 2018

CONDITIONS FOR USE OF TRANSCRIPTS:
This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections or check first with the speaker in question. If in doubt please contact the forum first.
## Contents

### About this Publication

3

### Agenda

4

#### Session Chair’s opening remarks

Glyn Davies MP, Member, All-Party Parliamentary Group on Parkinson’s [transcript] 6

#### Policy priorities for regenerative medicine and advanced therapies

Professor Sir Michael Rawlins, Chair, MHRA [transcript] 7

Questions and comments from the floor [transcript] 10

#### Key issues for research and development: investment, workforce and manufacturing

Dr Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult [transcript] 14

Dr Rob Buckle, Chief Science Officer, Medical Research Council and Director, UK Regenerative Medicine Platform [transcript] 17

Hugh Whittall, Director, Nuffield Council on Bioethics [transcript] 20

Dr Emily Culme-Seymour, Clinical Development Scientist, Gene Therapy, Rare Diseases Unit, R&D, GSK [transcript] 22

Professor Sian Harding, Network Lead, Stem Cell Regenerative Medicine Network; Professor, Cardiac Pharmacology and Interim Head of Department, National Heart and Lung Institute, Imperial College London [transcript] 24

Questions and comments from the floor [transcript] 26

#### Developing the regulatory structure: approvals, collaborative working and the relationship with the EU

Ian Rees, Manager, Inspectorate Strategy and Innovation Unit, MHRA [transcript] 34

Dr Amy Thomas, Head of Regulatory Development, Human Tissue Authority [transcript] 37

Questions and comments from the floor [transcript] 40

#### Session Chair’s closing remarks

Glyn Davies MP, Member, All-Party Parliamentary Group on Parkinson’s [transcript] 43

#### Session Chair’s opening remarks

Dr Amy Thomas, Head of Regulatory Development, Human Tissue Authority [transcript] 44

#### Next steps for the assessment of regenerative medicines and cell therapy products

Dr Nick Crabb, Programme Director, Scientific Affairs, NICE [transcript] 45

#### Priorities for NHS Blood and Transplant in supporting access to novel treatments

Dr Andrew Hadley, General Manager, Specialist Services, NHS Blood and Transplant [transcript] 48

#### Adoption in the NHS: communication, clinical infrastructure and patient involvement

Steve Ford, Chief Executive, Parkinson’s UK [transcript] 50

Questions and comments from the floor [transcript] 52

#### Next steps for regenerative medicine, advanced therapies and stem cell research

Professor Antonio Pagliuca, National Clinical Lead for Regenerative Medicine, NHS England; Consultant Haematologist, King’s College Hospital NHS Foundation Trust and Professor of Stem Cell Transplantation, King’s College London [transcript] 57

Questions and comments from the floor [transcript] 62

#### Session Chair’s and Westminster Health Forum closing remarks

Dr Amy Thomas, Head of Regulatory Development, Human Tissue Authority [transcript] 65

Stephanie Thomson, Senior Researcher, Westminster Health Forum [transcript] 66

#### List of Delegates Registered for Seminar

67

#### Contributor Biographies

71

#### About the Core Sponsors of the Westminster Health Forum

74

Please be advised that speakers’ PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker’s text. Please note that not all speakers are able to grant permission for us to include their slides.
About this Publication

This publication reflects proceedings at the Westminster Health Forum Keynote Seminar: The future for regenerative medicine, advanced therapies and stem cell research held on 17th April 2018. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

Westminster Health Forum
UK Headquarters
4 Bracknell Beeches
Old Bracknell Lane West
Bracknell
Berkshire RG12 7BW

T: 01344 864796
F: 01344 420121
publications@westminsterforumprojects.co.uk

Directors
Peter van Gelder
Chris Whitehouse